text:
- Text Size:
- ASmall Text
- AMedium Text
- ALarge Text
Severe storms are expected across Oklahoma for Mother's Day, mainly in the late afternoon and into the evening, even after sunset.
The image above shows the severe weather outlook for Oklahoma on Sunday. Even though Oklahoma is only under a "Slight" risk, this does not represent the intensity of the storms, but the amount of severe storms expected. This outlook does not guarantee that severe storms will occur, but it represents the area that severe storms are possible.
Look for isolates severe storms to develop in the late afternoon between 3-7 p.m. in northwestern Oklahoma. The severe weather risk includes:
- Isolated Storms
- Tornadoes
- 70 mph damaging winds
- Hail the size of baseballs
These storms will move and expand to the east during the evening, from 7-11 p.m. from western Oklahoma to I-35. On average, most tornadoes occur in the late afternoon and early evening. For Sunday, the tornado risk may continue several hours after sunset. The severe weather threat includes:
- Several Storms
- Tornadoes
- 70 mph damaging winds
- Hail the size of baseballs.
After 11 p.pm. the threat of tornadoes does decrease, along with the size of the damaging hail, but the risk for damaging winds will remain as storms merge into a larger cluster or clusters of thunderstorms. The severe threat will expand into central Oklahoma from 11 p.m. Sunday through 7 a.m. Monday to include:
- Large clusters of storms
- Low tornado risk
- 70 mph winds
- Ping pong size hail
- Flash flooding
With heavy rains coming into Oklahoma City Monday morning, motorists will want to look for areas of flash flooding. Never try to drive to flash flooding.


text:
Product Information
Mothers Day Gifts, Belgian Chocolate Covered Dessert Club Membership
The Chocolate Dip Delights 100& Real Chocolate Covered Dessert Club is a most delicious way to give a gift that celebrates the goodness of life each & every month of the year! Known for their rich, velvety Real Chocolates and unforgettable desserts crafted by artisan chocolatiers, this gift will have their heart melting with each and every bite.Available as a 3 month, 6 month, or full year subscription, the following gifts will be sent to your special someone each and every month to show that your love and affection is not only available to them on a specific day, but is there for them every second.Jan: Celebration Cupcakes.Feb: Red Drizzle Berries.Mar: Mixed Toppings Cake Pops.April: Easter Decorated Oreo Cookies.May:Cheesecake PopsJune: Mixed Chocolate Berries.July:Patriotic Decorated Oreo Cookies.Aug: Brownie Bites.Sept: Mixed Chocolate Covered Oreo Cookies.Oct: Halloween Cake Pops.Nov: Fall Chocolate Berries.Dec: Red Velvet Bites.
SHOP.COM ReviewsWrite a Review
This product has not yet been reviewed. Be the first to write a review.

subset: commoncrawl


text:
To which item(s) do you want to associate this flyer offer?
All selected items will be added to your shopping list.
This will allow you to get the flyer, the offers and the coupons available in your region.
extra virgin olive oil
beef tenderloin
sea salt and freshly ground black pepper
commercially prepared puff pastry rounds, 8 in. (20 cm)
slices of liver pate
eggs, beaten
extra virgin olive oil
chopped shallots
sliced white mushrooms
dry red wine
demi-glace sauce
Melt the butter in the oil and sear the beef tenderloins 1 minute per side. Season, remove and let cool.
Roll out the pastry rounds on a clean work surface.
Centre the liver slices on each round.
Top with a tenderloin.
Moisten the edges of the pastry with a little water and enclose the meat, sealing well.
Refrigerate the meat en croûte for 15 minutes.
Preheat the oven to 400°F (200°C).
Baste the pastry with the beaten eggs and bake in the oven for 20 to 30 minutes. Meanwhile, brown the shallots and mushrooms.
Deglaze with the red wine and reduce by half.
Add the demi-glace. Correct the seasoning. Serve the golden brown tenderloins en croûte on the sauce.
Accompaniments: steamed cauliflower and braised celery.
Medium or full-bodied red wine.
Source: Metro
Aromatic and supple
These medium-bodied wines are characterised by their smooth tannins that usually confer a certain roundness. They are often dominated by a nose of ripe fruit or woody notes (toast, coffee or vanilla).
Product category: red wine.
© Société des alcools du Québec, 2007
Metro Richelieu inc., its affiliated companies and affiliates are not responsible for any circumstance that should come up when using the suggested recipes. Each person using this site must check that each of the ingredients is allowed in his/her diet and is not part of his/her restricted foods.
All selected items will be added to your shopping list.
AIR MILES® program valid at any Metro location in Ontario excluding Thunder Bay.
®™ Trademarks of AIR MILES International Trading B.V. Used under license by LoyaltyOne, Inc. and Metro Ontario Inc.
Sorry, an error has occurred. Please refresh the page.
An error has occurred.
An unfortunate error with your shopping list occurred and the page must be refreshed. We apologize for the inconveniences.


text: Definitely glad this patriots can spell... -----Original Message----- From: funsec-bounces at linuxbox.org [mailto:funsec-bounces at linuxbox.org] On Behalf Of Jeffrey Walton Sent: Tuesday, November 30, 2010 10:06 AM To: FunSec Subject: [funsec] 'Patriotic' hacker claims credit for WikiLeaks attack http://technolog.msnbc.msn.com/_news/2010/11/29/5544493-patriotic-hacker-cla ims-credit-for-wikileaks-attack A single hacker is taking credit for the "mass distributed denial of service attack" that threatened to take down WikiLeaks shortly before its scheduled post of thousands of classified memos between U.S. diplomats. At approximately the same time WikiLeaks alerted its Twitter followers to the DDoS attack, "Jester," a self-proclaimed "hacktivist for good," sent this message from his Twitter account: @th3j35t3r (Jester) www.wikileaks.org- TANGO DOWN - INDEFINITLEY - for threatening the lives of our troops and 'other assets' _______________________________________________ Fun and Misc security discussion for OT posts. https://linuxbox.org/cgi-bin/mailman/listinfo/funsec Note: funsec is a public and open mailing list.


text:
Would you rather Sashaa smothered you with her tits or sucked your cock? Yeah, she'll do both, but what if you had to choose?
Posted by Dave on Jun 29, 2015 in Boob Bloopers, Hardcore XXX, Other SCORE Group websites, Tit Tricks
Let's consider this photo in an historical context. Meaning your history: How many girls have you seen who can do this? Sashaa's tits are covering nearly his entire face. Why does this guy have his thumbs up? Because he wants to let us know that he's still breathing, even though he's being smothered. Then again, maybe he's telling us that he isn't breathing but is perfectly fine with that because this is a great way to go.
We're not even halfway through 2015, and we've already had a lot of very happy returns to SCORELAND and XLGirls.com. Sashaa Juggs. Kendra Lee Ryan. Renee Ross. Valory Irene. Sashaa gained weight and gained tit, and for plumper lovers, that's always a good thing.
Okay, back to the photo: Has a girl ever done this to you? And if Sashaa said to you, "You can have this or a blow job," which would you take?
Of course, the great thing about Sashaa is that she'd never make you choose. With her, you can have everything.
And the answer to yesterday's Blog question is…Sashaa Juggs
Posted by Dave on May 12, 2015 in Cummin Soon, Hardcore XXX, New at Scoreland, newcomers, Uncategorized, XLGirls
Sashaa's tits are gigantic. They were always huge. Now they're legendary huge.
Sashaa returns to XLGirls.com Thursday.
Wednesday, another bustier returnee: Kendra Lee Ryan.
Yes, both girls will fuck. Eventually. But not this week. This week, we get to celebrate their returns and feast on their tits.
As for SCORELAND, the rest of the week is packed with superstars. Wednesday: Desiree Vega returns. Thursday: Sheridan Love fucks. Friday: Sandra Star. Saturday: Cat Bangles gets ass-fucked.
Life is good. Make sure you have a good supply of Kleenex.
He can't believe his eyes, and neither could I. Meet Sashaa Juggs!
Posted by Dave on Sep 8, 2012 in Behind the Scenes, Boob Watch, newcomers, Other SCORE Group websites, Tits in Tight Tops
When I first saw pictures of Sashaa Juggs, I said out loud, "Holy, shit!" Now, I've been at The SCORE Group for over 11 years, and it takes a lot for me to say, "Holy, shit!" (although I did say "Whoa!" the other day when I saw the rack on a girl who will make her SCORELAND debut next Wednesday). But Sashaa Juggs…this girl has everything you want in a great XL Girl: pretty face, big, fat tits, big, round ass, curves that go on forever…Sashaa Juggs is a "Holy, shit!" girl. She's packing. Her rack is huge, her body is big, she's blonde and she could be the girl-next-door. You can see her right now at XLGirls.com.
Sucking, fucking and taking a cock in her ass.
Holy, shit!
I'm not going to say anything else about Sashaa. I'm just going to enjoy this picture then head back over to XLGirls.com to watch her video. At one point in the video, she rests her huge rack on the guy's leg and then goes down on his dick. I can't tell you how much I enjoy seeing that.
Holy, shit!


text:
Holiday 2011 first look: messaging to bargain hunters
By now you've probably read the early forecasts predicting that the 2011 holiday season will be a subdued affair. The International Council of Shopping Centers predicts a 2.2% gain overall, down from 4.4% growth in 2010. ShopperTrak, which combines economic trends with foot traffic data, predicts 3% growth overall, compared with the 4.1% gain it reported in 2010.
But in a continuing trend, eCommerce promises to be a bright spot. According to Internet Retailer, research firm Kantar Retail predicts a 13.5% increase in online sales. Although that's a decline from the robust 16.5% growth Kantar reported in 2010, the 2011 forecast still holds out the promise of double-digit growth in an otherwise tepid year.
Forecasterss predict a rush of bargain hunters who will shop frugally and hold out for deals. As Jack Kleinhenz of the National Retail Federation told the Wall Street Journal, "There will be lots of promotions—that's become the norm."
To maximize the potential of online holiday sales in 2011, merchants should design their promotions with these savvy deal seekers in mind. That doesn't mean automatically dropping prices or eliminating barriers to free shipping; it does mean prominently communicating the value of your brand and products wherever shoppers roam.
1. Make it easy to seize opportunities across channels.
Gift guides, shareable wish lists and "save cart"/"print cart" options have long been part of merchants' holiday playbooks — but with shoppers doing more research than ever in advance of purchasing, it's crucial to fulfill their need for product and promotion information, in whatever format they seek it. In particular, don't neglect:
Page 1 of 4 | Next page


text:
J.P. Stewart - A new hobby: putting Windows XP in your car
- Posted: Oct 20, 2004 at 6:40PM
- 37 comments
Loading user information from Channel 9
Something went wrong getting user information from Channel 9
Loading user information from MSDN
Something went wrong getting user information from MSDN
Loading Visual Studio Achievements
Something went wrong getting the Visual Studio Achievements
Right click "Save as…"
Oops, something didn't work.
GLiNTCH wrote:NOW I have motivation to finally do it to my car, but I am estimating planning, design and deploy to last me into mid 2005.
Any thoughts on intergrating a PocketPC into the car?
Although one would want to use the VGA PPC's and probably needs to brush up on WinCE development to get a bigger secondary touch screen working right.
Or even go to a WinCE device and hack open the device to make the screen detachable and go from there...
hi J.P
For obdII you may check this link, it is using Windows CE
hi J.P
You check this link: Auto scan tool
It uses windows CE
Automotive Diagnostic Tools & Equipment
sinosells,the best place for online shopping from China.sinosells selling big brands of auto parts: auto auto diagnostic tool, ECU Tools, Locksmith Tools, Auto Accessories Digital Products, odometer correction, diagnostic scanner, auto scanner, immo code reader, airbag reset, transponder key, key blank.Please visit our website :http://www.sinosells.com/?u=1221 for more details. sionsells "faith-based,customer first, service first".
Comments have been closed since this content was published more than 30 days ago, but if you'd like to continue the conversation, please create a new thread in our Forums, or Contact Us and let us know.


text:
- Flat Rate Shipping. Any Size Order! -
- A Portion of Proceeds Benefit San Diego Athletics -
HOME San Diego Chargers Gear San Diego Chargers Mens San Diego Chargers Mens Home Office & School (17 items) Product ID: 1556669
Main Content
- Decorative use only (not a toy)
- Hand-painted details
- Imported
- Made of durable resin
- Measures approx. 12" long
- Officially licensed
- Raised printed logo decal
- Recommended for ages 13 or older
- Imported
- Brand: Forever Collectibles
Chargers Customers also liked:
Special event items are produced by manufacturers only after the outcome of a game or event. These are advanced sale items and will ship immediately after they are received in our warehouse.
Manufacturer direct items are shipped directly from the manufacturer. These items are not available for international or expedited shipping.
Customized items can be personalized with options such as your name, your favorite number, and/or designs. Some options may be limited by league rules.


text:
Michigan Beats Illinois 67-65 In…Football?November 6, 2010 – 4:45 pm by McD
Want to know how to give up 65 points, 316 rushing yards, 88 offensive (OFF-ensive, not of-FEN-sive, though some definitely were) plays, 562 total yards, and five turnovers while still winning? Just ask the Michigan Wolverines.
I can say with certainty after this game that this is, without a doubt, the worst defense I've ever seen. Worse than any unit Indiana University has ever fielded. In fact, I hope they set some kind of record for bad defense because this is a unit I think we all want to remember forever.
Michigan fan really has to be wondering if this is the situation they want. Sure, Rich-Rod's boys are winning more games now and Denard Robinson is awesome, but the only way they'll win anything substantial ever is through shootouts like this. And they'll still get punked by Ohio State every November because the Buckeyes' defense is too good.
Wolverine fan might have to come to terms with the fact that the program of Schembechler and Lloyd Carr is, dare we say it, soft.
Even though Illinois lost, doesn't 5-4 seem about as good as it's going to get for the Illini? That's not exactly a program with a lot of tradition there. As an Indiana grad, I know from lack of football tradition.
So, as painful as that probably was for Illinois fan, things really aren't all that bad in the grand scheme of things. They're nearly bowl eligible with a redshirt frosh quarterback and new defensive and offensive systems. That's pretty good after the abomination that was the Juice Williams Era.
And Michigan won, but they have to be feeling the exact opposite. The evolution of this program from the staid, boring style of Lloyd Carr to the modern spread offense is surprisingly Nebraska/Bill Callahan-like and one more bowl-less season away from a total disaster.
So, you know, enjoy the win, fellas.
*Photo courtesy AP


text:
Office / Department Directory
The Administrative Offices and Departments of South Texas College are part of a solid foundation that have helped the college grow and succeed over the past ten years. The members of these offices and departments work diligently to provide services and resources to students, STC faculty and staff, and members of the community. Should you need additional information or help from a particular office or department, please use to links provided to visit their respected webpages.
The Office of the Vice President for Academic Affairs
The Office of the Vice President for Student Affairs and Enrollment Management
The Office of the Vice President for Finance & Administrative Services
The Office of the Vice President for Information Services and Planning
Grant Development, Management & Compliance
The Office of Public Relations and Marketing
The Office of Professional & Organizational Development


text: Share Your Story: Sally Sharp by Christy D. on Monday, June 10, 2013 Sally Sharp Missouri I died on January 19, 2011. My story begins on a typical school day...nothing was out of the ordinary and the day was going according to plan. Then, that all changed. I was sitting in my classroom beginning to eat lunch with some of my co-workers. Things began to go terribly wrong. I felt myself falling to the floor, with no prior warning signs. None of my fellow teachers knew CPR so one of them ran out of the room in search of the head school nurse. She came running into my room and started administering CPR on me to get my heart started again. The school nurse's quick thinking along with other life-saving procedures, started my heart beating again. I was transported by ambulance the hospital where I spent the next five days for extensive testing to find out the cause. It has since been diagnosed and under control. I have lost 63.8 pounds since October 8, 2011. I strongly support the American Heart Association's initiative to teach CPR to students and I hope my story inspires you and others to live heart-healthy. « Now share your story Share This


text:
7 Comments
It definitely looks like some ancient alien icon. Something from Flash Gordon. +1 for the resurrection.
lovin' the colors! I'd like one of these as well!!!!
BenjaminPhantom Artist from Florida, United States
I like this one! Voted.
66rockstar Human
Like the colors alot!
Briodman445 Human
I would like to order 3,198 of these.
Sweet design!


text:
1AEPM00053-A/C Bypass Pulley
hablamos español:
Read More
1997-2002 Jeep Wrangler A/C Bypass Pulley for L6 4.0L1AEPM00053-481058
This part replaces:
- Dorman 34237
- New
This Bypass pulley bolts on to your engine in the same location as your malfunctioning Air Conditioning compressor, allowing you to use your original serpentine belt. A malfunctioning compressor can be noisy and cause premature damage to your serpentine belt. This is a cost effective alternative to costly repairs to your Air conditioning system.
- Built to strict quality control standards
- Includes bracket, highest quality bearing, and correct size pulley
- Fits perfectly in the place of an A/C compressor.
- Allows you to use your original serpentine belt
- Includes mounting hardware
Lifetime Warranty
This item is backed by a Limited Lifetime Warranty. In the event this item should fail due to manufacturing defects during intended use, we will exchange the part free of charge (excludes shipping charges) for the original purchaser. Please keep your invoice for proof of this warranty.
Vehicle Fit
- 1996-2002 Dodge Dakota A/C Bypass Pulley for L4 2.5L
- 1996-2000 Jeep Cherokee A/C Bypass Pulley for L4 2.5L
- 1996-2000 Jeep Cherokee A/C Bypass Pulley for L6 4.0L
- 1997-2002 Jeep Wrangler A/C Bypass Pulley for L4 2.5L
- 1997-2002 Jeep Wrangler A/C Bypass Pulley for L6 4.0L
Part #: 1AEPM00053
Ships Same Day for orders placed by 5 P.M. ET
Free GROUND SHIPPINGCheck Shipping Rates
We're here to help
Call Toll Free
hablamos español:
Customer Feedback
"Thanks for the fast reliable service. Great price, and the headlights were as good as oem or better!!! Keep up the good work..."- Dwuan M.
Read More


text:
May 9, 2012
Bud Light may have just simultaneously created the easiest and best marketing campaign ever. The official beer sponsor of the National Football League is offering one fan two season tickets to their favorite team's regular season home games for up to 50 years beginning with the 2013 NFL season.
The deal is so sweet, they're even throwing in a season parking pass.
To enter, fans aged 21 and up only have to fill out an online entry form on Bud Light's Facebook page, or on their website. Seriously.
Entries will be accepted through January 11, 2013, with the lucky winner announced before Super Bowl XLVII.
"There's nothing like cheering your favorite team from the stands on game day, and we're going to make sure one of our fans enjoys that experience for life," said Mike Sundet, vice president, Bud Light. "We're giving fans the opportunity to enter throughout the 2012 season because we want every single NFL fan to have the chance to throw their name in the hat." (via Press Release)
Official rules can be found on Bud Light's website.


text:
Buddy if you hit the money they will pay you if you are a resident of Canada or the United States..
Originally Posted by 4kec4: i need to ask a question about picking moneyline.say team 1 vs. team 2 are playingteam 1 is 17.5+ and team -17.5. does that mean team 2 has to win witha 18 pts difference . im talking about college football
How did you get in here?
Copyright © 1995-


text:
The vacant big-box building on Rivers Avenue in North Charleston that once housed Sam's Club before it moved next to the Tanger Outlet Center is being renovated for a new home-decor store.
Houston-based Garden Ridge plans to move into the space in Aviation Square, according to people familiar with the expansion.
The 53-store chain offers a broad assortment of furniture, framed art, home textiles, decorative accessories, holiday decorations and garden decor.
Garden Ridge is privately held by AEA Investors of New York. Neither the company nor its investors responded to requests for comment about the new store at 6185 Rivers Ave.
The chain's website gives little indication of the new store, except for a hint of one in the Charleston area. In a selection among South Carolina sites in the query section, it offers a choice of Charleston or Greenville, where the other store is located.
The building under renovation measures about 104,000 square feet and is next door to Virginia College. Benderson Development Co., which is leasing the property, could not be reached for comment.
Garden Ridge was started in 1979 as Garden Ridge Pottery.
Food lines
The Starfish Grille will close Saturday, but the restaurant site on James Island won't stay vacant long. Owner Justin Parfrey plans to reopen the restaurant at 520 Folly Road near Harbor View Road with a new concept called Salty Waters Rawbar & Grill either Tuesday or Wednesday.
The former Huddle House in St. Stephen is now the Happy House restaurant. Owned by Kim Dye, the home-style restaurant at 3980 Byrnes Drive near the Post Office offers breakfast, lunch and dinner except on Sunday.
Eileen's restaurant at 10597 Dorchester Road, near Bacons Bridge Road in Summerville, recently closed. A new Japanese-style restaurant reportedly will occupy the site.
Best Chefs in America has opened its headquarters on the second floor of 218 King St. The annual publication profiles top chefs and their restaurants and will be the "ultimate chef's guide to chefs," according to Best Chefs President Brad W. Norton. The first edition should be available this year. The 2,400-square-foot space will house a staff of 20 and could grow larger.
Wheeling in
A new skate shop and clothing boutique is coming to downtown Charleston. Viln Collective will open Saturday at 5071/2 King St. To launch the new shop, co-founders Daniel Blackwell and William Zimmer IV will host a grand opening party from 7 to 11 p.m. Saturday. It will feature drinks, live music from "Rocky Horror" and Jeff ET as well as a pop-up shop from nearby retailer Jamie Lin Snider.
The shop will cater to men and women with skates and supplies, clothing, shoes and accessories.
Pet project
Tractor Supply Co. is offering specials and giveaways through Sunday as part of its second annual "Pet Appreciation Week" promotion.
Two customers at each of the Brentwood, Tenn.-based company's stores will win a $200 store gift card or a $100 vet services rebate from Hills Science Diet. Also, one online grand prize winner will drive away with a new Ford F-150 King Ranch pickup truck and a year's supply of Purina pet food.
The main event is Saturday, with pet specials, nutrition demonstrations, pet adoptions and giveways.
Do you know of a business that is opening, closing or expanding? Reach Warren L. Wise at 937-5524.


text:
The What song are you Test
Tests others are taking
ASensationalGuy42 / m / Straight
Jackelms23 / m / Straight
Seina144 / f / Straight
The Did I Make Obvious Mistakes on My OKCupid Profile? Test
kosmoloko36 / m / Straight
The LaVey Personality Synthesizer test
jstrange226 / m / Straight
Connect your existing OkCupid account
Sign in
Welcome Back!
Restore your account to continue meeting new people.
Reset your password
We'll email you a link to reset it.
Email sent!
An email is on its way to .
If you don't see it, try checking your Spam folder.
Enter Authentication Code
Sign in
Not so fast!
You need to complete your basic info on the mobile app before you can use the desktop site.


text:
12 Comments
lmilustraciones Artist from Buenos Aires, Argentina
muy buen trabajo +1
Cool i like it +1
Support me back please
CornyMistick Artist from United Kingdom
Nice colors, +1
great design
great artwork!
Chevinster Artist from Colombo, Sri Lanka
Beautiful +1
Please vote/comment
Birds (Click Here)
CD vs Cassette (Click Here)
Cool. +1
woow cool +1 check my design thanks!!!
notahuman82 Artist from Athens, Greece
cool graphic!+1
Need your support,check my Cosmic ice cream for vote and feedback:
Nice stuff +1


text:
Ohio State University students discover stranger, 'Jeremy', living in their share house
- From: news.com.au
- September 18, 2013
AT LEAST he was a "nice guy" named Jeremy and not a really creepy dude.
Students at a US university share house were shocked to find a strange man living in a secret bedroom in the basement of their home without their knowledge.
For months the roommates had heard strange noises - 'dings' and 'alarms' - emanating from behind a locked doors, the housemates told The Lantern.
They told their mates they had a ghost. Until they became suspicious enough to ask their landlord to open up the locked door.
Do you have a crazy sharehouse story? Tell us: email@example.com
Inside was a typical boy's bedroom: a mattress, clothes everywhere and photos on the wall of 'Jeremy' and his family.
The landlord left a note for Jeremy asking him to call him. He moved out shortly after.
The roommates are just relieved it wasn't a "dangerous" situation.
"He was a really nice guy, I feel bad for him," said resident Brett Muggin. "But you know. He wasn't supposed to be living here."


text:
May 16, 2009
Healthy Facts About Digestion And Weight
What is Digestion?
Digestion is the process of breaking down components of food into smaller, absorbable parts. The process of digestion is a chemical and mechanical process in which the components of food are broken down into a form that can be easily digested by the human body. These components of food are broken down into a form that can be absorbed by the blood. When broken down, the food is no more in its original form. When the components are absorbed by the blood, the minerals, vitamins, carbohydrates, fats, proteins and salts are supplied to the various organs of the body for functioning.
Reason Of Over Weight:
The weight of a person is the result of what a person eats, how much exercise the body gets and the amount of intake of food. The weight depends on Basal Metabolic Rate, commonly known as the BMR. Digestion and weight are related through the Basal Metabolic Rate index. Basal metabolic Rate is the quantity of energy extracted from the food that we eat, after its absorption takes place in our body. This energy that is released is just enough for the vital organs of the body to perform their respective functions. BMR Is measured when a person is at rest.
The vital organs of the human body include the heart, nervous system, brain, kidneys, lungs, liver, skin and the muscles. It is a known fact that the basal metabolic rate declines with increasing age. Digestion is the factor on which the basal metabolic rate depends. If food digestion in a person is effective and fast, the person has a lower basal metabolic rate. On the other hand, if food digestion in a person is slow and inefficient, the person is bound to have a higher body mass index. People with body mass index under a certain level are categorized as being of normal weight.
Those people who have a body mass index higher than the normal, within a specified range are said to be overweight. When the body mass index exceeds this specified limit, a person is said to be obese. Obese people are those whose intake of food is much more than what their body system can digest. The energy from the food they eat is not extracted completely and is stored as fat. Also, that energy which is extracted is not spent due to lack of exercise and hence results in obesity. Therefore, effective digestion is the key the correct body weight.
Written by: slaich2000
Filed Under: Digestion
Tags: lose weight
Trackback URL: http://www.easy16.com/healthy-facts-digestion-weight/trackback/
May 21, 2009 at 2:35 am
Nice explanation of digestion and why people get overweight and the importance of physical fitness and exercise.
- Pregnancy Nourishment, is it Fake, Fiction or Factual? | HEALTH TIPS & GUIDES 05-30-2009 at 5:25 am
- This 06-10-2009 at 10:01 pm


text:
Twenty years ago, two men, one toting a sawed-off shotgun, the other wielding a pistol, barged into Frank's Deli. Paul Kang, whose parents bought the place in the 1980s, remembers being so scared during the robbery that he trembled for the rest of day.
Frank's hasn't been robbed since, but there is crime all around in Camden's Waterfront South neighborhood, where men sell drugs on street corners. In January 2011, 20-year-old Anjanea Williams was shot dead outside Frank's, caught in the cross fire between drug dealers.
"It might be impossible to do, but I think just going back to the old school, and having cops walk the beat and be a presence . . . it deters crime," Kang said, sipping his fourth cup of coffee one afternoon as customers bustled around.


text:
A sobriety checkpoint set up in Canyon Country by the California Highway Patrol Friday night resulted in one arrest and four misdemeanor citations, a CHP spokesman said.
Between 6:30 p.m. Friday and 2:30 a.m. Saturday, CHP officers stopped "hundreds" of motorists at sobriety checkpoint on Sierra Highway at Vasquez Canyon Road, said CHP Officer John Lutz.
"We made one (driving under the influence) arrest," Lutz said. "As well, we issued four misdemeanors including two for driving without a licence and two for driving with an open container (of alcohol)."
In a news released issued in advance of the checkpoint, motorists were advised that they if approached the checkpoint they could expect to see informational signs advising them of a sobriety checkpoint ahead. They were also told that once diverted into the lane, they would be detained only momentarily while an officer explains the purpose of the checkpoint.
Comparatively, CHP officers from the Newhall station arrested seven people with driving under the influence of alcohol between Friday and Sunday. Deputies, in the same period, arrested three people for impaired driving, according to the arrest log issued by the Los Angeles County Sheriff's Station.
The goal of the DUI Checkpoint is to create awareness among the motoring public, to deter people from driving under the influence, and to keep the streets safe for all. Although checkpoints tend to reduce the number of drinking drivers on the road, the CHP will apprehend DUI drivers who fail to heed our warnings. Even though arrest totals do not rise dramatically, the psychological influence a checkpoint has on the motoring public is invaluable.
Sobriety checkpoints are conducted in accordance to the guidelines for checkpoint operations outlined in the Supreme Court decision, Ingersol vs. Palmer.
on Twitter @jamesarthurholt


text:
All fonts in the Adobe Type Library can be embedded in Adobe Portable Document Format (PDF) files, as well as other types of electronic documents. Many can also be modified for internal use. Click here for a list of the specific permissions for all fonts in the Adobe Type Library.
Font Embedding: OpenType fonts contain information in the actual font file that reinforces what is specified in the Adobe end user license agreement (EULA) and governs how these fonts may be embedded in electronic documents. According to the OpenType specification, four possible permission settings can be included in an OpenType font (from most restrictive to least restrictive):
No Embedding: This permission signals that the font or any portion of the font may not be embedded in any electronic document. While there are no fonts in the Adobe Type Library with this permission, some third-party font foundries may set their fonts to ???no embedding??? or prohibit embedding through their end user license agreement.
Preview & Print: A font with an embedding permission of Preview & Print allows the font, either fully or as a subset, to be embedded in an electronic document solely for the purpose of viewing that document on screen and/or printing that document. While a font with a Preview & Print embedding permission (either through data in the font file or the font??s license agreement) may be embedded in an electronic document, the embedded font may not be used to further edit the document it is contained in or to edit or create other documents. Most fonts in the Adobe Type Library are set for Preview & Print embedding.
Editable: Fonts with an editable embedding permission can be embedded in electronic documents, and the embedded font can then be used by the recipient of the electronic document to view, print and further edit or modify the text and structure of the document in which it is embedded. These changes or edits can then be saved in the original document. Several fonts in the Adobe Type Library, including all Adobe Originals typefaces, other Adobe-owned typefaces and certain third-party font foundry typefaces, allow for editable embedding.
Installable: Fonts with an installable embedding permission may be embedded in electronic documents for viewing, printing and editing, with the added capability that they may be also be permanently installed on the computer that receives the electronic document containing the embedded font. This allows the font to be used to create and author new documents. It is intended that the recipient of a font set to installable embedding obtains all of the same rights as the person who originally licensed the font.
Please note that different font creators or third-party foundries may grant different embedding permissions, either in the font or through their end user license agreement, even though Adobe Acrobat may be technically able to embed either the entire font or a subset of that font. To determine whether a given font can legally be embedded in a PDF document or other file, you should contact the licensor from whom you obtained your license rights to use the font software. Click here for information on how to determine third-party font licensors.
Font Modification: Many, but not all, Adobe fonts in the Adobe Type Library can be modified with some restrictions. Click here for a list of the specific permissions for all fonts in the Adobe Type Library If the font software you wish to modify is identified as "licensed for modification" you may also modify the font software, provided that such modified software is used only for your own customary internal business or personal use and will not be distributed or transferred for any purpose, except in accordance with the End User License Agreement that came with the font software.


text:
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages.
The personalized medicine (global) market is presented as follows:
A wealth of financial data & business strategy information is provided including:
SWOT, Economic & Regulatory Environment specifics include:
This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.
What you will gain:
This report tackles key concerns to the personalized medicine market such as:
Who should read this report?
This report will tell you if the companies mentioned are:
This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine.
Table of Contents
1.0 Executive Summary 111.1 Objectives of Report 111.2 Scope of Study 121.3 Data Sources and Methodology 131.4 Key Findings and Observations 13
2.0 Introduction 172.1 Pharmacogenetics 182.2 How Personalized Medicine Monitoring can Reduce Adverse Drug Reactions 252.3 Pharmacogenetic Study Challenges 262.4 Pharmacogenomics 262.5 Applications of Pharmacogenomics 272.5.1 Pharmacogenomics: Improving the Safety of Medications 2184.108.40.206 Adverse Drug Reactions 2220.127.116.11 Pharmacogenomics: Improving the Efficacy of Therapeutics 282.6 Pharmacogenetic Analysis 322.6.1 Single Base Primer Extension 322.6.2 Primer Based Base Extension 322.6.3 Hybridization Based SNP Analysis 332.6.4 Ligation Based Approach 342.6.5 New-Generation Sequencing Technologies 352.6.6 Ultra-High Throughput Sequencing 352.7 Companion Diagnostics
3.0 Personalized Medicine Therapeutics and Companion Diagnostics 443.1 CYP2C9 and VKORC1 mutations and Warfarin Response 443.2 HLA-B*5701 and Abacavir Response 453.3 KRAS Mutations 463.3.1 Erbitux 473.3.2 Vectibix 473.4 Herceptin® and Breast Cancer 473.5 BRACAnalysis® 593.5.1 Comprehensive BRACAnalysis® 623.5.2 BRACAnalysis® Rearrangement Test (BART) 623.5.3 Single Site BRACAnalysis® 623.5.4 Multisite 3 BRACAnalysis® 623.6 Oncotype Dx Test 623.7 Therascreen® EGFR RGQ PCR Kit 623.8 Therascreen KRAS RGQ PCR System 633.9 Therascreen® IDH1/2 test 633.10 THxID™ -BRAF Kit 63 3.12 Cobas® EGFR Mutation Test (Roche) 643.13 Prolaris Prostate Cancer Test 64
4.0 Personalized Medicine and Integration into the Healthcare System 654.1 The Personalized Medicine Coalition 654.2 Personalized Medicine and the Healthcare System 674.3 Clinical Application of Personalized Medicine 674.4 Clinical Laboratory Improvement Amendments-Certified Laboratory of Genomic Pathology 68
5.0 Private and Public Funding and Personalized Medicine Reimbursement 705.1 International Research and Development Personalized Medicine Activity 705.1.1 Publically Funded Personalized Medicine Research 705.1.2 Privately Funded Personalized Medicine Research 715.2 Popular Biological Targets/Pathways in Pharmacogenetic/Pharmacogenomic Research 765.3 Equitable Payer Reimbursement 785.3.1 Molecular Diagnostic Payments in Personalized Medicine126.96.36.199 RVU-CPT-ICD Coding System 785.3.2 Laboratory Service Payments in Personalized Medicine 785.3.3 Revisions to Current Payment System 785.4 Biorepositories and Biobanks 785.5 Intellectual Property and Personalized Medicine 79
6.0 European Personalized Medicine Market – Payments and Investment 806.1 Personalized Medicine and The European Market 806.2 European Investment in Personalized Medicine 816.3 Overview of Reimbursement Policies in Europe 816.4 Gaining Market Penetration in the EU 826.5 Personalized Medicine Regulation and Reimbursement in the UK 876.6 CE-marked Personalized Medicine/Diagnostic Tests in the UK 926.7 Personalized Medicine Regulation in Germany 926.8 Personalized Medicine Regulation in France 946.9 Personalized Medicine Regulation in Spain 946.10 The Personalized Medicine Regulation in Italy 946.11 Challenges of Future Personalized Medicine Development 95
7.0 Personalized Medicine –Business Model Analysis 967.1 New Business Model Required for Personalized Medicine 967.2 Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies 977.3 Business Model Strategies for Providers. Provider Systems and Academic Medical Centres 977.4 Business Model Strategies for Payers 987.5 Business Model Strategies for Governments 987.6 Introduction of Non-Health Companies to the Personalized Medicine Market 987.7 Change to the Big Pharma Business Model 997.8 Cost-effectiveness and Business Value of Personalized Medicine 997.9 Comparative Effectiveness Research in Personalized Medicine 100
8.0 Personalized Medicine Main Industry Players 1028.1 23andMe 1028.2 Affymetrix 1038.3 Astex Pharmaceuticals 1058.4 Atossa Genetics 1078.5 CuraGen 1088.6 Celera Corporation (Quest Diagnostics) 1088.7 Celldex Therapeutics 1098.8 deCode Genetics (Amgen) 1108.9 Illumina 1118.10 Genelex 1128.11 Myriad 1138.12 Nodality 1148.13 Qiagen 116
9.0 Personalized Medicine Industry Products and Kits 1199.1 23andme 1199.2 Affymetrix 1269.3 Astex Pharmaceuticals 1279.4 Atossa Genetics 1289.4.1 Mammary Aspirate Specimen Cytology Test (MASCT™) 1289.4.2 ForeCYTE Breast Health Test (SM) 1289.4.3 ArgusCYTE Breast Health Test(SM) 1289.4.4 FullCYTE Breast Health Test 1289.4.5 NextCYTE Breast Health Test 1299.5 Celera (Quest Diagnostics) 1299.5.1 ViroSeq® HIV-1 Genotyping System 1299.5.2 ViroSeq® HIV-1 Integrase Assay 1309.5.3 ViroSeq® HCV Assay 1309.5.4 ViroSeq® HBV Assay 1309.5.5 Cystic Fibrosis Genotyping Assay 1309.5.6 LDL-S3GGE® Test 1319.5.7 HDL-S10GGE® Test 1319.5.8 KIF6-StatinCheckTM Genotype Test 1319.5.9 9p21-EarlyMICheckTM Genotype Test 1319.5.10 LPA-AspirinCheckTM Genotype Test 1319.5.11 AlleleSEQR® HLA PCR/Sequencing Kits 1319.5.12 m2000® RealTime PCR System 1329.5.13 CEGA -16™ Instrument 1339.6 deCode Genetics 1339.6.1 deCodeT2 Genetic Test 1349.6.2 deCODE Breast Cancer™ 1349.6.3 deCODE Prostate Cancer™ 1359.6.4 deCODE AF™ 1359.6.5 deCODE Glaucoma™ 1359.6.6 deCODE MI™ 1359.6.7 deCODE Complete™ 1369.6.8 deCODE Cancer™ 1379.6.9 deCODE Cardio™ 1379.6.10 deCODE Services 1379.7 Illumina 1389.7.1 Illumina HiSeq 2000/1000 1399.7.2 Genome Analyzer IIx 1409.7.3 Illumina MiSeq 1419.7.4 Illumina HiScanHQ 1429.7.5 Illumina HiScan and iScan Array 1429.8 Genelex 1439.8.1 You Script™ 1439.9 Myriad Genetics 1459.9.1 BRACAnalysis® 1459.9.2 COLARIS®/COLARIS AP® 1469.9.3 MELARIS® 1479.9.4 PANEXIA® 1479.9.5 OnDose® 1479.9.6 PREZEON™ 1479.9.7 THERAGUIDE® 5FU 1479.9.8 Prolaris® 1489.10 Nodility 1489.11 Qiagen 1489.11.1 Genotyping Products 1499.11.2 QIAsymphony Platform
10.0 Personalized Medicine Market Analysis 15410.1 General Overview 15410.2 Personalized Medicine Market Forecast 15410.3 Personalized Medical Care Market Forecast 15610.4 Personalized Medicine -Nutrition and Wellness Sub-Market Forecast 15610.5 Personalized Medicine -Diagnostic and Therapeutic Sub-Market Forecast 15710.6 Global Personalized Medical Technology Market Forecast 15710.7 Global Personalized Medicine Sub-market Growth Forecast 15810.8 Molecular Diagnostics Market 16010.9 Consumer Genomics Market 16010.10 Market Participant Analysis 16110.10.1 23andme 16110.10.2 Affymetrix 16310.10.3 Astex Pharmaceuticals 17310.10.4 Atossa Genetics 17610.10.5 Celera (Quest Diagnostics) 17910.10.6 Celldex Therapeutics 18510.10.7 deCode Genetics (Amgen) 18710.10.8 Illumina 18810.10.9 Genelex 19110.10.10 Myriad 19210.10.11 Nodality 19610.10.12 Qiagen 19810.10.13 bioMerieux 202
11.0 Strengths and Advantages of Personalized Medicine 21011.1 Sequencing of the Human Genome in 2000 21011.2 Improving Patient Care and Reducing Side Effects 21011.3 Personalized Medicine will Reduce Healthcare Costs 21011.4 FDA Advances in Personalized Medicine Regulation 21011.5 Advancing Technologies 21111.5.1 Next Generation Sequencing 21111.6 Industry Investing in Pharmacogenomics 21211.7 Consumer Genomics and POC Market 21211.8 Oncology a Driving Force of Personalized Medicine 213
12.0 Restraints of the Personalized Medicine Market 21512.1 Lack of Sufficient Regulation 21512.2 Lack of Sufficient Genotypic Linkage Studies to Disease Phenotype 21512.3 Reimbursement Issues 216
13.0 Personalized Medicine and Regulatory Policies 21713.1 Regulation 21713.2 Genetic Information Non-discrimination Act (GINA) 21713.3 FDA Advancements on Genetic Testing Approval 21913.4 FDA- New Models to Assess Gene Therapy Safety 22213.5 FDA- Companion Diagnostics 22213.6 FDA - Partnership in Applied Comparative Effectiveness Science (PACES) Initiative 222
14.0 Final Summary and Future Perspectives 223
List of Tables
Table 2.1: Quick Facts: Personalized Medicine 18Table 2.2: Genetic Mutations that Predispose Individuals to Disease 19Table 2.3: Potential Applications of Pharmacogenetics and Pharmacogenomics in Personalized Medicine 19Table 2.4: Main Cytochrome P450 Enzymes Involved in Drug Metabolism 19Table 2.5: QUICK FACTS: Rapid & Slow Metabolizer Phenotypes 20Table 2.6: Population Frequency of Cytochrome P450(CYP) 2C19 Metabolizer Types 21Table 2.7: Population Frequency of Cytochrome P450 (CYP) Metabolizer Types 21Table 2.8: Depression Medications Affected by Genetic Mutations 21Table 2.9: Cardiovascular Medications Affected by Genetic Mutations 22Table 2.10: Cancer Medications that may be Affected by Genetic Mutations 22Table 2.11: Diabetes Medications Affected by Genetic Mutations 23Table 2.12: Anti-Epileptic Drugs Affected by Genetic Mutations 23Table 2.13: Anti-Retroviral Drugs Affected by Genetic Mutations 23Table 2.14: Anti-Reflux/Ulcer Drugs Affected by Genetic Mutations 23Table 2.15: List of Therapeutics According to Cytochrome P450 Subtype Metabolism 24Table 2.16: Cytochrome (CYP) P450 Drug-Interactions Inhibitor List 25Table 2.17: Cytochrome (CYP) P450 Drug-Interactions Inducer List 25Table 2.18: QUICK FACTs - Main Aims of Pharmacogenomics 26Table 2.19: How Pharmacogenomics has Influenced the Top Ten Selling Drugs Globally 28 Table 2.20: Advantages, Disadvantages and Cost of Popular Genotyping Methods 28Table 2.21: QUICK FACTS - Top Ten Pharmacogenomics Tests 29Table 2.22: QUICK FACTS - FDA Accepted Pharmacogenomic Biomarkers 29Table 2.23: QUICK FACTS - Benefits of Single Base Primer Extension in Pharmacogenetics 32Table 2.24: Future Applications of Ultra-High Throughput Sequencing 36Table 2.25: QUICK FACTS - Comparison of Genotyping Techniques 36Table 2.26: Problems associated with Microarray Sequencing 36Table 2.27: QUICK-FACTS - Top Ten Genetic Findings of 2010 by 23andMe 36Table 2.28: FDA Companion Diagnostics Device List: In Vitro and Imaging Tools 37Table 2.29: Important Strategies for a Successful Companion Diagnostic Launch 43Table 3.1: Predicted Warfarin Concentrations depending on CYP2C9 and VKORC1 Genotype 45Table 3.2: QUICKFACTS - Top Five Most Frequent Cancers in Men and Women, Globally 48Table 3.3: QUICKFACTs - Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer per Country, Worldwide 50Table 3.4: QUICK-FACTS - Types of Diagnostic Tests Available to Determine HER2 Status in Breast Cancer Patients 55Table 3.5: Validated HER2 Tests for Cancer 57Table 3.6: QUICK FACTS - Advantages and limitations of IHC HER2 testing applied to breast cancer 57Table 3.7: In-Situ Hybridization Determination of HER2 Expression by PathVysion® and HER2 FISH pharmDxTM 58Table 3.8: HER2 CISH Determination 58Table 3.9: Validated FISH Kits for HER2 Testing in Breast Cancer 58Table 3.10: Validated SISH Kits for HER2 Testing in Breast Cancer 58Table 3.11: Validated CISH Kits for HER2 Testing in Breast Cancer 58 Table 3.12: Advantages and limitations of ISH techniques applied to HER2 testing in breast cancer 59 Table 3.13: QUICK FACTs- Prevalence of Deleterious Mutations in BRCA1 and BRCA2 Genes 59 Table 3.14: QUICK FACTs- prevalence of deleterious mutations in BRCA1 and BRCA2 in individuals of Ashkenazi Ancestry 60Table 3.15: QUICK FACTs- Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC) 61Table 3.17: QUICKFACTs- BRACAnalysis® Panel of Assays 62Table 3.18: The Prolaris Score for Prostate Cancer 64Table 4.1: QUICKFACTs - Objectives of the Personalized Medicine Coalition 65Table 4.2: Current Personalized Medicine Coalition Members 65Table 4.3: Genetic Variants used in care of melanoma, gastrointestinal stromal tumors, non-small-cell lung cancer, thymic cancer and breast and ovarian cancers. 67Table 4.4: Minimum Definition of a clinically Actionable Variant 68Table 4.5: Minimum Criteria for Whole Genome Analysis in Clinical Laboratory Improvement Amendments Laboratory of Genomic Pathology, Clinical Whole Genome Analysis 69Table 5.1: Public Funding Bodies for Pharmacogenetic/Pharmacogenomic Research 71Table 5.2: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Drug Development and Diagnostics 72Table 5.3: European Companies Involved in Pharmacogenomics/Pharmacogenetics Drug Development and Diagnostics 72Table 5.4: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Diagnostics 72Table 5.5: European & Other Companies Involved in Pharmacogenomics/PharmacogeneticsDiagnostics 73Table 5.6: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Services 73Table 5.7: European/Other Companies Involved in Pharmacogenomics/Pharmacogenetics Services 73Table 5.8: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Tools Kits and Software 74Table 5.9: European Companies Involved in Pharmacogenomics/Pharmacogenetics Tools Kits and Software 74Table 5.10: North American Companies with Minor interest in Pharmacogenomics/Pharmacogenetics 74Table 5.11: European/Other Companies with Minor interest in Pharmacogenomics/Pharmacogenetics 75Table 5.12: Large US Companies with Investment into Pharmacogenomics/Pharmacogenetics 75Table 5.13: Large European Companies with Investment into Pharmacogenomics/Pharmacogenetics 76Table 5.14: Large Japanese Companies with Investment into Pharmacogenomics/Pharmacogenetics 76Table 5.15: Top Ten Biological Areas of Interest in Pharmacogenetics/Pharmacogenomics 76Table 5.16: Top International Pharmacogenetic/Pharmacogenomic Research Institutions 77Table 5.17: Top European Pharmacogenetic/Pharmacogenomic Research Institutions 77Table 6.1: QUICK FACTs- Variation of Reimbursement Policies for HER2 and KRAS Testing in Europe 81Table 6.2: Pharmaceutical Companies Providing Subsidization of Diagnostic Personalized Medicine Tests in Europe 82Table 6.3: QUICKFACTs - Challenges Within Personalized Medicine Market in Europe 83 Table 6.4: QUICKFACTS- Function of the European network for Health Technology Assessment (EUnetHTA) Organisation 83Table 6.5: European network for Health Technology Assessment (EUnetHTA) Partners 84Table 6.6: European network for Health Technology Assessment (EUnetHTA) Associates 86Table 6.7: Diagnostics Guidance Assessment by the National Institute for Health and Clinical Excellence (NICE) 88Table 6.8: Current Diagnostics Guidance in Development by the Diagnostics Access Program, UK 89Table 6.9: Published Diagnostics Guidance by the Diagnostics Access Program, UK 90Table 6.10: Medical Technologies Guidance Assessment by the National Institute for Health and Clinical Excellence (NICE) 90Table 6.11: Published Medical Technologies Guidance by the National Institute for Health and Clinical Excellence (NICE) 91Table 6.12: Published Medical Technologies Guidance in Development by the National Institute for Health and Clinical Excellence (NICE) 91Table 6.13: QUICK FACTs - Key Challenges to Personalized Medicine 95Table 6.14: QUICKFACTs - Personalized Medicine - Translation into Medical Applications 95Table 7.1: QUICK FACTS - Major Market Trends in Personalized Medicine 96Table 7.2: Collaboration Strategies Required between Industry, Payers and Governments for a Productive Personalized Medicine Market 96Table 7.3: QUICK FACTs - Business Model Recommendations for Diagnostic, Pharmaceutical and Biotechnology Companies 97Table 7.4: QUICK FACTs - Business Model Recommendations for Providers. Provider Systems and Academic Medical Centres 97Table 7.5: QUICK FACTS Business Model Recommendations for Payers 98Table 7.6: QUICK FACTs - Business Model Recommendations for Governments 98Table 7.7: QUICK FACTs - Non-Healthcare Companies with Potential to enter the Personalized Medicine Market 99Table 7.8: Hurdles of Personalised Medicine with Respect to Cost-Effectiveness 100Table 8.1: Patent Listing of Affymetrix Array technology 104Table 8.2: Patent Listing of Affymetrix Genotyping Technology 104Table 8.3: Patent Listing of Affymetrix Array technology 105 Table 8.4: Patent Listing of Affymetrix Genotyping Technology 106 Table 8.5 Astex Pharmaceuticals Pipeline Portfolio 106Table 8.6: Astex Pharmaceuticals Pipeline Portfolio Funded Completely by Partner Companies 107Table 8.7: Potential Business Partnerships of Celldex Therapeutics 109Table 8.8: Illumina Core Technologies 111Table 8.9: Illumina Core Technology Applications 111Table 8.10: Illumina Instrument Product Portfolio 112Table 8.11: Illumina Assay Product Portfolio 112Table 8.12: Genetic Test Panel Available from Genelex for Research Institutions and Clinical Trials 113Table 8.13: Pre-Clinical, Clinical and Commercial Applications of SCNP by Nodality 116Table 8.14: Qiagen Timeline of Events, 1994-2012 116Table 8.15: QUICKFACTs - Range of Product Groups from Qiagen 118Table 9.1: 23andMe Disease Risk Genetic Test Panel 119Table 9.2: 23andMe Carrier Status Genetic Test Panel 122Table 9.3: 23andMe Drug Response Genetic Marker Test Panel 124Table 9.4: 23andMe Genetic Traits Test Panel 124Table 9.5: QUICKFACTs - Product Overview of Affymetrix 126Table 9.6: Microarray Products by Affymetrix 126Table 9.7: Affymetrix Research Services Laboratory (ARSL) Premier Services 127Table 9.8: Genetic Applications of Axiom® Technology by Affymetrix 127Table 9.9: Range of Small Molecule Therapeutics Available from Astex Pharmaceuticals 127Table 9.10: Panel of cystic fibrosis transmembrane conductance regulator (CFTR) mutations screened for in Celera Cystic Fibrosis Genotyping Assay 130Table 9.11: Genetic Tests Available from BHL/Celera 132Table 9.12: Panel of BHL Clinical Diagnostic Tests 132 Table 9.13: Features of the m2000® RealTime PCR System by Celera 132Table 9.14: Genetic Diagnostic Tests Available from deCode Genetics 133 Table 9.15: Type 2 Diabetes risk range and distribution according to continental ancestry as Determined by deCodeT2 Genetic Test 134Table 9.16: Genetic Mutations Identified by the deCODE MI™ Test in a European Population 135Table 9.17: Genetic Mutations Identified by the deCODE MI™ Test in an East Asian Population 136Table 9.18: Disease States that are Included in the deCODE Complete™ Genetic Screen 136Table 9.19: Panel of Diseases Screened for in the deCODE Cancer™ Test 137Table 9.20: Panel of Cardiovascular Diseases in the deCODE Cardio™ Test 137Table 9.21: deCODE Genetics Genotyping and Sequencing Service 137Table 9.22: deCODE Genetics Data Management, Protection and Storage Service 138Table 9.23: deCODE Genetics Sequence Inputation and Data Analysis Service 138Table 9.24: Illumina HiSeq 2500/1500 Performance Parameters 139Table 9.25: Illumina HiSeq 2000/1000 Performance Parameters 139Table 9.26: Genome Analyzer IIx Performance Parameters 140Table 9.27: Illumina MiSeq Product Specifications 141Table 9.28: Illumina HiScanHQ Product Specifications 142Table 9.29: Illumina HiScan and iScan Array Product Applications 142Table 9.30: Illumina iScan Array Kits 142Table 9.31: Panel of Genetic Screens Available from Genelex 144Table 9.32: Drug Sensitivity Screens Available from Genelex 144Table 9.33: Predictive Genetic Tests Available from Myriad 145Table 9.34: Services offered with BRACAnalysis® Testing from Myriad 145Table 9.35: Advantages of BRACAnalysis® Testing 146Table 9.36: COLARIS® Test Range by Myriad 146Table 9.37: COLARIS AP® Test Range by Myriad 147Table 9.38: MELARIS® Test Range from Myriad 147Table 9.39 Personalized Medicine Tests from Myriad 147Table 9.40: OnDose® Testing Procedure from Myriad 148Table 9.41: Qiagen Genotyping Products for Sample Collection, stabilization and Storage 149Table 9.42: Qiagen Genotyping Products for Genomic DNA Isolation and Purification 149Table 9.43: Qiagen Genotyping Products for PCR Based Genotyping Analysis 150Table 9.44: Qiagen Products for Genotyping Analysis 150Table 9.45: Qiagen Genotyping Products for PCR Detection 151Table 9.46: Qiagen Assays for Genetic Analysis 151Table 9.47: Qiagen Pyrosequencing-Based Genetic Analysis Products 151Table 9.48: Specifications and Features of Qiagen's QIAsymphony and QIAsymphony RGQ 152Table 10.1: QUICK FACTs - Submarkets within the Personalized Medicine Technology Market 157Table 10.2: Drug Classes Investigated by 23andMe using genome wide association studies 162Table 10.3: Acquisition Profile of Affymetrix 164Table 10.4: Genetic Applications of Axiom® Technology by Affymetrix 164Table 10.5 Diversified Business Units of Affymetrix 165Table 10.6: Affymetrix AgBio Microarray Portfolio 167Table 10.7: Celera (Quest Diagnostics) Historic Operating (Loss) (US$) – Laboratory Services andProducts 2008-2010 183Table 10.8: Diagnostic Test Product Categories Manufactured by BHL/Celera and Exclusively Distributed by Abbott 183Table 10.9: Celldex Therapeutics R&D Expenses ($) 2010-2012 186Table 10.10: Price Listing of Genelex Familial Genetic Tests 191Table 10.11: Myriad - Core Business Decisions and Impact on Industry 2012 195Table 10.12: Future Test Portfolio of Myriad 195Table 10.13: Nodality's Single Cell Network Profiling (SCNP) Technology as a Systems Based Biology Approach to Drug Discovery and Validation 197Table 10.14: BioMerieux Immunodiagnostic Product Portfolio 202Table 10.15: BioMerieux Microbiology Product Portfolio 204Table 10.16: BioMerieux Molecular Diagnostic Product Portfolio 206Table 11.1: QUICK FACTS: Strengths and Advantages of Genotyping Techniques 211Table 11.2: QUICK FACTS: Strengths, Drivers and Advantages of Personalized Medicine Market 213Table 12.1: QUICKFACTs: Restraints of Personalized Medicine Market 216Table 13.1: QUICK FACTS - Summary of Clinical Laboratory Improvement Amendments (CLIA) 217Table 13.2: Clinical Laboratory Improvement Amendments (CLIA) Testing Categories 218Table 13.3: QUICK FACTS - Test Features required prior to FDA Approval and Clearance 218Table 13.4: Impact of Genetic Information Non-discrimination Act (GINA) on Healthcare Companies and Health Plans 219Table 13.5: Impact of Genetic Information Non-discrimination Act (GINA) on US Employers, employment agencies, labor organizations and training programs 219Table 13.6: QUICK FACTS - FDA Commitment to the Personalized Medicine Industry 220Table 13.7: Objectives of the 'Advancing Regulatory Science at FDA: A Strategic Plan' 220Table 13.8: QUICKFACTS - Implementation Strategy of the FDA to Advance Regulatory Science - Develop better Models of Human Adverse response 221Table 13.9: QUICKFACTS - Implementation Strategy of the FDA to Advance Regulatory Science - Identify and evaluate biomarkers and endpoints that can be used in non-clinical and clinical evaluations 221Table 13.10: QUICKFACTS - Implementation Strategy of the FDA to Advance Regulatory Science - Use and develop computational methods and in silico modelling 221
List of Figures
Figure 2.1: QUICK FACTS - Elements of Personalized Genomic Medicine 17Figure 2.2: Identification of Good and Non-Responders in a Patient Population 20Figure 2.3: Pharmacodynamic and Pharmacokinetic Examples of Drug Targets and Drug metabolism in Pharmacogenomics 27Figure 2.4: QUICK FACTS - Flow Diagram of Pharmacogenetic Analysis 32Figure 2.5: Primer Based Base Extension in Pharmacogenetics 33Figure 2.6: Genetic Mutation Detection by Hybridization 34Figure 2.7: Ligation based SNP Detection 34Figure 2.8: New-Generation Sequencing: Pyrosequencing 35Figure 3.1: QUICK FACTS - Warfarin Metabolism and Response 44Figure 3.2: QUICK FACTS - Percentage Frequency of CYP2C9 and VKORC1 mutations in Caucasian, African-American and Asian Populations 45Figure 3.3: QUICK FACTS: Anti-EGFR Therapy and KRAS Mutations 46Figure 3.4: KRAS and BRAF Genetic Tests Available from Asuragen 47Figure 3.5: Global Incidence and Mortality of Cancer in Women 48Figure 3.6: Cancer Deaths in Women, Globally according to Cancer Type 49Figure 3.7: Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer Globally 49Figure 3.8: HER2 Testing Algorithm for Breast Cancer 56Figure 3.9: HER2 Cellular Signalling 56Figure 3.10: QUICKFACTs - Herceptin – Mechanism of Action 57Figure 3.11: BRCA Mutation Increases the Risk of Breast and Ovarian Cancer 61Figure 3.12: Proactive Cancer Management and Preventative Measures Reduces the Risks of Developing BRCA-associated Breast and Ovarian Cancer 61Figure 4.1: Integration of Multiple components for a Personalized Medicine Healthcare System 66Figure 4.2: Workflow Diagram illustrating Clinical Laboratory Improvement Amendments-Certified Laboratory of Genomic Pathology 68Figure 4.3: Hypothetical Flow Diagram of a Patient through the Genomic Pathology Clinical Laboratory 69Figure 5.1: Personalized Medicine Scheme Interaction with Industry, Regulatory Bodies and Funding Agencies 70Figure 5.2: Number of Publically Funded Pharmacogenetic and Pharmacogenomic Research Teams Internationally 71Figure 6.1: Adverse Drug Reactions are the Fourth Leading Cause of Death 80Figure 6.2: Efficacy Rate of Major Disease Types with Standard Treatment 80Figure 6.3: The In Vitro Diagnostic Market in Europe 83Figure 6.4: QUICK FACTS: Organization of the European network for Health Technology Assessment (EUnetHTA) 84Figure 6.5: Key Differences in Reimbursement Policy Approaches for Oncology Diagnostics and Therapeutics in Europe and the US 89Figure 6.6: Flow Diagram of the German Healthcare System and Key Agencies 93Figure 6.7: German Reimbursement Arrangement, Process and Implications 93Figure 7.1: Annual Healthcare Expenditure for Major Industrial Nations 101Figure 7.2: Estimated Life Expectancy from Birth for Major Industrialized Countries 101Figure 8.1: Celldex Therapeutics Product Pipeline 110Figure 8.2: Single Cell Network Profiling (SCNP) Technology by Nodality 115Figure 8.3: Developed Functional Assays that Nodality has explored using new SCNP Technology 115Figure 9.1: Flow Diagram of Celera CEGA -16™ Instrument for Cystic Fibrosis Gene Analysis 133Figure 9.2: Percentage of Individual Populations who have an Increased Risk of Developing Type 2 Diabetes as Determined Using the deCodeT2 Genetic Test 134Figure 9.3: Illumina New Generation Sequencing Technology Workflow Station 138Figure 10.1: Combined Personalized Medicine Market in the US, 2009-2015 155Figure 10.2: Core Personalized Medicine Sub-Market Growth Forecast 2009-2015 155Figure 10.3: Personalized Medical Care Sub-Market Growth Forecast 2009-2015 156Figure 10.4: Nutrition and Wellness Sub-market of Personalized Medicine Growth Forecast 2009-2015 156Figure 10.5: Diagnostic and Therapeutic Personalized Medicine Market Growth Projection in the US, 2009-2015 157Figure 10.6: Global Market Personalized Medicine Technology Growth Forecast 2009-2015 158Figure 10.7: Global Personalized Sub-market Growth Forecast 2009-2014 158Figure 10.8: Personalized Medicine Sub-Market Share (Percentage) 2009 159Figure 10.9: Personalized Medicine Sub-Market Share (Percentage) 2014 159Figure 10.10: Global Molecular Diagnostics Predicted Market Share 2015 160Figure 10.11: Global Molecular Diagnostics Market Projection 2015 160Figure 10.12: Private Funding Gained by 23andMe 2007-2012 161Figure 10.13: Affymetrix Revenue by Business Segment (Percentage), 2013 168Figure 10.14: Affymetrix Revenue by Business Segment (Percentage), 2012 168Figure 10.15: Affymetrix Total Revenue 2007-2013 169Figure 10.16: Affymetrix Revenue by Product Division – Consumables, Instruments 2010-2012 169Figure 10.17: Affymetrix Core Product Sales – Gene Expression, Genetic Analysis & Clinical Application and Life Science Reagents, 2011-2012 170Figure 10.18: Affymetrix Revenue Derived from Outside the US, 2009-2012 170Figure 10.19: Affymetrix Revenue Derived from the US, 2009-2012 171Figure 10.20: Affymetrix Net Loss, 2009-2012 171Figure 10.21: Affymetrix Research and Development Funding, 2009-2012 172Figure 10.22: Affymetrix Revenue Generated within USA (Percentage) 2010-2012 172Figure 10.23: Astex Pharmaceuticals Priority Pipeline Products SGI-110 and AT13387 by Indication, Clinical Phase and Timeline 173Figure 10.24: Astex Pharmaceuticals Revenue Generated 2008-2012 175Figure 10.25: Astex Pharmaceuticals Net Income 2009-2012 175Figure 10.26: Atossa Genetics Total Revenue (US$) 2011, 2012 177Figure 10.27: Atossa Genetics Revenue (US$) Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012 178Figure 10.28: Atossa Genetics Percentage Revenue Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012 178Figure 10.29: Quest Diagnostics Revenue ($ Billions) 2008-2013 180Figure 10.30: Quest Diagnostics Operating Revenue ($ Billions) 2008-2013 181Figure 10.31: Quest Diagnostics Net Income ($ Billions) 2008-2013 181Figure 10.32: Celera (Quest Diagnostics) Historic Revenue Generated 2008-2010 182Figure 10.33: Celera (Quest Diagnostics) Historic Gross Margin Generated 2008-2010 182Figure 10.34: Celera (Quest Diagnostics) Historic Revenue Generated– Laboratory Services and Products 2008-2010 183Figure 10.35: Celera (Quest Diagnostics) Historic Revenue (%) Generated by Distribution Agreement with Abbott 2008-2010 184Figure 10.36: Celera (Quest Diagnostics) Historic Research and Development Spending 2008-2010 184Figure 10.37: deCode Genetics Historic Net Loss Incurred 2004-2008 188Figure 10.38: Illumina Revenue Generated ($ Billions) 2010-2013 190Figure 10.39: Illumina Net Income Generated ($ Billions) 2010-2013 190Figure 10.40: Myriad Revenue Generated 2007-2014 194Figure 10.41: Operating Income Generated by Myriad 2007-2014 194Figure 10.42: Myriad Revenue Generated by Molecular Diagnostic Testing and Companion Diagnostic Services, 2012/2013 195Figure 10.43: Future Molecular Diagnostic Pipeline of Myriad 196Figure 10.44: Customer Profile of Qiagen – Percentage of Net Sales 2012/2013 200Figure 10.45: Qiagen Global Net Sales 2007-2013 201Figure 10.46: Qiagen Operating Income 2007-2013 201Figure 10.47: Qiagen Global Net Income 2007-2013 202Figure 11.1: Percentage Oncology (Lung, Colorectal, Breast, Prostate) Patients Undergoing Next Generation Sequencing Testing in the US, 2018 212Figure 11.2: Pipeline and On-market Oncology (Lung, Breast, Colorectal, Prostate) Therapeutics Directed Against Specific Mutations, 2013 214
Did you find what you are/were looking for
If not, read below and browse through other relevant pages for similar market research
reports OR get in touch with us through the form/contact info in your right navigation
panel and we�ll share relevant market report titles for you to explore.
Epigenetics Market by Product (Modifying Enzymes, DNA Polymerase, Acetylase, Methyltransferase, Instruments & Consumables, Kit, Bisulphite Conversion Kit, Reagents), by Research Area (Developmental Biology, Oncology) - Global Forecast to 2020The epigenetics market is expected to reach USD 890.0 million by 2020 from USD 469.6 million in 2015, at a CAGR of 13.64% between 2015 and 2020. By product, the market includes enzymes, instruments & consumables, kits and reagents. Enzymes are... Companion Diagnostics in Personalized Medicine and Cancer TherapyCompanion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug,... Companion Diagnostics and Other Aspects of Personalized MedicineThe focus of this report is the use of personalized medicine for pharmacological/diagnostic combinations; particularly pharmacological therapies and the diagnostic tests, which can provide information on the likelihood of a patient to respond to s... Companion Diagnostics - Streamlining drug development and advancing personalized medicineCompanion Diagnostics - Streamlining drug development and advancing personalized medicine
Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around The Complete Guide to Companion Diagnostics: Market Environment Products and CompaniesWhile 'personalised medicine' (or theranostics) is not new it is only relatively recently that diagnostics companies and pharma have converged to explore and exploit its potential benefits. By using companion diagnostics, companies can... Companion Diagnostics and Personalized Medicine Market Report 2012Up-to-Date Market Analyses of the CDx FieldThis is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace. Personalized me... World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the r... Combination Drug Diagnostics: Fueling Growth of Personalized MedicineReport Description:The focus of this report is on drug/diagnostic combinations -- drugs used to treat patients, and ondiagnostic tests that can provide information about how a patient may respond to treatment with tha...
The epigenetics market is expected to reach USD 890.0 million by 2020 from USD 469.6 million in 2015, at a CAGR of 13.64% between 2015 and 2020. By product, the market includes enzymes, instruments & consumables, kits and reagents. Enzymes are...
Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug,...
The focus of this report is the use of personalized medicine for pharmacological/diagnostic combinations; particularly pharmacological therapies and the diagnostic tests, which can provide information on the likelihood of a patient to respond to s...
Companion Diagnostics - Streamlining drug development and advancing personalized medicine
Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around
While 'personalised medicine' (or theranostics) is not new it is only relatively recently that diagnostics companies and pharma have converged to explore and exploit its potential benefits. By using companion diagnostics, companies can...
Up-to-Date Market Analyses of the CDx FieldThis is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace. Personalized me...
In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the r...
Report Description:The focus of this report is on drug/diagnostic combinations -- drugs used to treat patients, and ondiagnostic tests that can provide information about how a patient may respond to treatment with tha...
Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.
Get Email alerts about market research reports from industries and publishers of
your interest:


text:
It was a difficult day for family and friends as they said goodbye to a Lancaster family killed in a July 4 fire. Click here to watch Chris Hush's story.
Entire family laid to rest after Lancaster fire
Published On: Jul 16 2013 12:39:15 PM EDT
Copyright 2013 by WGAL All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
The views expressed are not those of this site, this station or its affiliated companies. By posting your comments you agree to accept our terms of use.blog comments powered by Disqus


text:
on September 11, 2010 - 12:01 AM
1. San Francisco 49ers (15.0)
Offense: Everything revolves around RB Frank Gore, who is coming off his fourth straight 1,000-yard season. The 49ers drafted more blocking help in RT Anthony Davis and RG Mike Iupati. TE Vernon Davis and WR Michael Crabtree give QB Alex Smith a chance to thrive. Grade: 3.0.
Defense: ILB Patrick Willis is a flat-out stud. Takeo Spikes is an excellent complement. NT Aubrayo Franklin is an ideal 3-4 space-eater. The Niners had 44 sacks in '09 (third in NFL) without a star pass rusher. CB Nate Clements' high salary overshadows improving young secondary. Grade: 4.0.
Special teams: K Joe Nedney, 37, keeps rolling along. P Andy Lee is Mr. Reliable. Ted Ginn Jr. should revive return game. Grade: 4.0.
Coaching: Mike Singletary's toughness and passion for the game has rubbed off on players. Grade: 4.0.
On the spot: Smith. It's now or never for 2003 No. 1 overall draft pick.
Prediction: The division is there for the taking. Record: 10-6.
2. Arizona Cardinals (14.0)
Offense: Kurt Warner's retirement and Matt Leinart's release put Cleveland castoff Derek Anderson under center. At least he's got a great target in WR Larry Fitzgerald. Anquan Boldin is gone, but youngsters Steve Breaston and Early Doucet are ready to fill in. RBs Beanie Wells and Tim Hightower need to generate running game. Grade: 3.0.
Defense: DEs Darnell Dockett and Calais Campbell (seven sacks each in '09) and rookie NT Dan Williams are a formidable three-man front. OLB Joey Porter will have plenty of pass rush opportunities. CB Dominique Rodgers-Cromartie and SS Adrian Wilson are rock-solid in the secondary. Grade: 4.0.
Special teams: K Jay Feeley and P Ben Graham thrive in warm weather. LaRod Stephens-Howling handles return duties. Grade: 3.0.
Coaching: Despite losses, Ken Whisenhunt will find a way to keep team competitive. Grade: 4.0.
On the spot: Anderson. Replacing Warner is impossible task.
Prediction: Even with QB issues, a favorable schedule gives them a chance. Record: 7-9.
3. Seattle Seahawks (13.0)
Offense: Everything depends on the health of QB Matt Hasselbeck, who has missed 11 games the past two seasons. LT Russell Okung was drafted sixth overall to protect Hasselbeck. TE John Carlson is best receiver after WR T.J. Houshmandzadeh was released in part because of the remarkable career revival of former draft bust Mike Williams. RB Justin Forsett must provide ground game. Grade: 3.0.
Defense: LBs Aaron Curry and Lofa Tatupu are all that's left from an overhauled front seven. CB Marcus Trufant is good when healthy and rookie FS Earl Thomas may be a future star. But trading CB Josh Wilson weakens the secondary. Grade: 3.0.
Special teams: Leon Washington is a great addition to the return game. Age hasn't affected K Olindo Mare's leg. Grade: 4.0
Coaching: If nothing else, Pete Carroll brings a college-type enthusiasm. Grade: 3.0.
On the spot: DE Chris Clemons. Seahawks desperately need a pass rush from him.
Prediction: Seahawks hope to at least be competitive. Record: 6-10.
4. St. Louis Rams (10.0)
Offense: Workhorse RB Steven Jackson returns after back surgery due in large part to having to carry the team on it (NFC-high 1,416 yards and team-high 53 catches). Top draft pick Sam Bradford is a talent, but he lacks proven receivers or an O-line to protect him. Grade: 2.0.
Defense: MLB James Laurinaitis's surprisingly strong rookie year (120 tackles, two sacks, two INTs) was the lone bright spot. The Rams were wise to re-sign FS Oshiomogho Atogwe, but he alone can't save generous secondary. Grade: 1.5.
Special teams: The kicking game is a positive with K Josh Brown and P Donnie Jones. Rookie Mardy Gilyard's speed will upgrade return game. Grade: 4.0.
Coaching: Steve Spagnuolo can't implement pressure tactics with limited talent. Grade: 2.5.
On the spot: DE Chris Long. It's time Howie's boy played like the No. 2 overall pick in the 2008 draft.
Prediction: Nowhere to go but up, but it's a long climb. Record: 2-14.


text:
How Sears adjusts the supply chain model for an omnichannel reality
Floating Widget
Floating Item Container
Floating Rate Widget
Your Rating
It might have taken a week of scouring online reviews to finally decide which refrigerator to buy, but once you place your order at Sears.com, you'll have it in your home the very next day. That's what Raj Penkar, SVP and President, Supply Chain of Sears Holdings Corporation is working hard each day to make a reality.
In front of a packed room at the NRF Global Supply Chain Summitthis morning, Raj described how Sears adjusted its supply chain model to better deliver on its marketing promises – that no matter how, when or where you shop, you'll get the same great experience and the goods in hand quickly. Fulfilling that promise is the task of the supply chain, Raj says, but to do it effectively, supply chain professionals have to be a little innovative.
Sears has piloted a few new supply chain models that leverage existing inventory and existing retail distribution centers, meaning a small number of store locations now fulfill online orders. More than 90 percent of online orders for big-ticket items are delivered the next day using a network of nearly a dozen of what Sears calls direct delivery centers and marketing delivery operations across the nation. So even if an order comes in at 5 p.m., a direct delivery center (DDC) ships the item to the marketing delivery operation (MDO) in the customer's neck of the woods, and by the next morning, a trained technician is delivering and installing your fridge.
For smaller items, Sears checks the nearest store capable of shipping first. Though Raj said stores can't reach the same level of efficiency as a DC, with a few adjustments and some trained staff members, a small number of Sears' stores include a sort of "mini-DC" that allows the store personnel to fulfill orders. Online orders from the region go first to this fully equipped store for fulfillment and to a DC if the inventory isn't available from the store.
The model has been successful for Sears, along with other strategies to leverage existing inventory, assets and real estate, such as modifying retail distribution centers to fulfill online orders as well.
When fielding questions from the audience, Penkar stressed the importance of selecting a small number of stores that fulfill a large number of online orders, and then equipping those stores with the resources and staff needed to do the job well. After all, the goal is to provide a seamless customer experience regardless of where an order comes from. That's the challenge of the integrated, or omnichannel, retail supply chain of today.
Recent @NRFnews
Retail sales at clothing and accessory stores increased 0.7% in August, driven by the #backtoschool spending season. https://t.co/8n5pyfw4jn2 hours ago Reply Tweet Favorite
September retail imports expected to be at near-peak levels despite #Hanjin bankruptcy. https://t.co/w5lYvfdfjD #supplychain3 hours ago Reply Tweet Favorite


text:
A Lebanon man is charged in the armed robbery of a pawn shop in the city, according to police.
Officers said they were called to Ken's Gold Mine in the 800 block of Quentin Road at 2 p.m. Tuesday.
Edwin Vasquez-Santana, 20, robbed the business at gunpoint and left with an undetermined amount of cash, police said.
Investigators said he tried to take a bicycle from a 40-year-old woman in the area of 800 Cornwall Road as he fled the robbery scene.
Vasquez-Santana is charged with two counts of robbery. He is in Lebanon County Correctional Facility with bail set at $100,000.


text:
A "drooling, droopy-eyed" Nick Nolte was arrested on suspicion of driving under the influence of drugs or alcohol Wednesday, after police allegedly spotted his black 1992 Mercedes-Benz swerving across a Malibu highway.
"An officer making a traffic stop on Pacific Coast Highway heard tires squealing and saw the vehicle driven by Nolte approaching rapidly, weaving across all lanes and into opposing traffic," California Highway Patrol spokesman Leland Tang tells Reuters.
"The officer made stopped the vehicle and found that Mr. Nolte at that point seemed completely out of it," Tang said. "He was drooling, (with) droopy eyes. He ... looked very much like he was under the influence."
According to the Associated Press, Nolte, 61, who failed a field sobriety test, remained in custody until about 8:30 p.m. Wednesday, at which time he was cited and released.
The actor's publicist, Arnold Robinson, told AP he had no immediate comment.
"He was extremely pleasant and cooperative," Tang said of Nolte to Reuters. "Apparently there were even a few passersby and one of the passersby stopped and took pictures."
Nolte Arrested on DUI Charge in Malibu


text:
Stay Tuned On the Go!
SPB TV offers quick and easy access to live and on-Demand video services. Superior features like convenient channel store, social accounts integration, instant channel preview, picture-in-picture mode for quick browsing, and integrated TV guide makes SPB TV the perfect product for watching live TV on the go.
Get for free (5 MB)
1 of 12Next →
Main Screen
- Unique TV browser with quick channels preview for fast channel selection
- Picture-in-picture mode
- Finger-friendly onscreen controls for one-handed navigation
- Channels from more than 20 countries
- Integrated TV guide
- Clever integration of mobile TV functionality with other mobile phone features
- Fast channels launch and switching


text:
The Website Coordinator's general duties include creating video content, including features, press conferences, and news pieces, keeping the website fresh with the newest content possible, creating new features, managing the blog and podcast program, and general maintenance of Canucks.com and RogersArena.ca.
Because the web is now such a large source of information, many departments within the Canucks organization also use the website to promote their events or any information they want people to know. One of the best parts of this job is the opportunity to work with many different people and interact with different departments such as Creative Services, Marketing, or Hockey Operations.
There is no typical day in the Canucks web department, which is another great aspect of the job. There is something new happening everyday and a big part of this position is being able to think quick on your feet and move forward.
On non-game days, if there are practices, the Web Assistant attends practice to gather quotes from players and coaches for news or feature stories. The remainder of the day consists of posting content on the web and handling requests from other internal departments. This could be something like a ticket promotion or a community event we want to get featured on the site.
On game days, the website staff turns their focus on game-related content and priority always goes to the morning skate and getting all the news to prepare for the game on the website. Usually, it includes putting together a couple of videos and writing a news story. Once this is complete, the Web Assistant's priorities shift to regular content and maintenance until the game starts.
Most of the activity on a game-day happens post-game, when the Web Assistant must to go into the dressing room to get more quotes and video. The web department stays late to prepare all the post-game information, including a recap, two videos, a photo gallery, and a post-game side bar story.
Because the Web Assistant position is mostly content-based, a degree or diploma in journalism or communications is helpful. Beyond formal education, having good interpersonal skills and being flexible to changing situations is an asset. Situations don't always go as planned so being able to think quickly and adapt to different circumstances makes the job a lot easier. More often than not, there are many things happening at once, which means being able to juggle multiple projects and prioritizing is a necessity.
In addition, the Web Assistant is constantly learning, whether on a technical or personal level, being able to adapt to the always changing and evolving web industry.


text:
NEW YORK (Standard & Poor's CreditWire) March 21, 2001--Standard & Poor's today assigned its double-'A' rating to Tulsa County Independent School District No. 9, Okla.'s $12 million building bonds (Union Board of Education) series 2001 due May 1, 2006. The bonds are scheduled to sell March 26, 2001. The outlook is stable. In addition, Standard & Poor's affirmed its double-'A' rating on the district's building bonds. The rating is based on the full faith and credit of the district and reflects: -- A diverse regional economy with sustained strong district tax base growth, -- Above-average wealth and income levels, -- Strong financial management despite state restrictions on reserve levels, and -- Low overall debt levels coupled with rapid five-year principal...
Companies mentioned in this report are:
- Tulsa Cnty Indpt Sch Dist No 9 Union
Action: New Rating
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.
- Tulsa Cnty Indpt Sch Dist No 9 Union


text:
Deejay Crush is a Dj from Belgium (Maldegem)
He started at the age of 14 at home.
have turned up on birthday party's,clubs in and around Ghent.
It started with : club,house,electronic,techno
after the years I changed my style to music : progressive house, trance,minimal, techno,tech house,retro,groovy
I also am going to concentrate on making music.
Press play to try again.
You can get it here.


text:
'Those were the days, my friend, we thought they'd never end'
Deaglán de Bréadún
In these difficult times, everyone needs a good laugh now and then. They say it is the best medicine of all. In that spirit, I am offering the introductory paragraph of then-Taoiseach Bertie Ahern's statement when he announced an increase in the number of junior ministers from 17 to 20 on 20 June 2007.
Brian Cowen in happier times with 18 of the 20 outgoing ministers of state (Photograph by Dara MacDonaill, 13 May 2008)
"In determining the Ministers of State to be recommended for appointment by the Government, I have taken account of the growing burdens on Ministers and Ministers of State as a result of the greater complexity of the policy agenda, the management pressures in giving political direction to extensive Government programmes, the time requirements for the extensive legislative programme of this Government, the increasing engagement in terms of accountability with Oireachtas Committees and the extensive engagement with stakeholders at all levels, both domestically and in Europe. As a result, I have decided to increase the total number of Ministers of State to twenty, from the previous limit of seventeen. Legislation to give effect to this increase was approved by the Government this morning."
If you can avoid sniggering when you read the above, then you have a truly saintly or otherwise superhuman disposition. I recall the day in question very well. There had indeed been a Cabinet meeting that morning where it was decided to up the number of "juniors" from 17 to 20. But nobody, not even the Government spokesman of the day, knew that the appointments would be announced after a secret Cabinet meeting that afternoon.
Even the chosen ones themselves did not know of their good fortune until they received the summons, as one of them revealed, at about 10.30 in the morning. Told to be in Government Buildings, the lucky backbencher finally heard the news officially at 3.50pm. By the end of the day, out of 78 Fianna Fáil TDs, 32 had the word "minister" attached to their names in one form or another.
There was remarkably little public reaction at the time, except for some negative comments in the media and from the Opposition. Richard Bruton of Fine Gael pointed that over the lifetime of the Government each of the new juniors would cost the tax payer an extra €4 million. The €12 million that would be spent could buy 700,000 home-help hours or provide 23,000 extra families with medical cards.
Labour's Joan Burton highlighted the ludicrous side of it all when she said: "The Department of Education and Science has five Ministers of State and one Minister. The Department of Health has four Ministers of State and one Minister. The Department of Justice, Equality and Law Reform kicks in with another four Ministers of State, and the Department of Enterprise, Trade and Employment has another four Ministers of State.
"I do not know if the Taoiseach was having a laugh when he provided the Department of Education and Science with five Ministers of State." Each of them would have "advisers, press attaches and personnel to hold their hand and carry out ministerial duties".
Fianna Fáil's Martin Mansergh responded that the last Rainbow Coalition of FG, Labour and Democratic Left had increased the number of ministers of state to 17, including an extra super-junior who could attend cabinet meetings.
But among the wider public there was very little comment. What a different story now when every conceivable perk or helping of "pork" arouses widespread anger and the politicians are very much on the run from an outraged public opinion.
Brian Cowen is now about to cut the number of ministers of state from 20 to 15. All will be revealed this week. Not before time: public opinion leaves him with no other option.


text:
Baloney on Obamacare
September 8, 2013
A recent letter titled "Obamacare's hidden tax" is based on misinformation still being spread by a thoroughly debunked viral email....
13 Democrats Charged With Embezzling $16 Million In Federal Grants For AIDS Charities And Other Needy Programs! Daughter of Reverend "God*****America" Wright Among Those Charged.
Quinshaunta R. Golden, former Illinois Department of Public Health chief of staff. Charges: Bribery/theft, mail fraud and obstruction of justice. Details: Golden, a niece of U.S. Rep. Danny K. Davis (D-Ill.), is accused of pocketing about $433,000 in kickbacks on health department contracts and grants that she oversaw.
These and other Dems are accused of stealing the money for personal use including mortgage and credit-card payments, vacation home payments, and in one case, a Mercedes-Benz, a Cadillac and a fur coat.
Thank god the Democrats are taking over the entire health care system country wide! They're so trustworthy.
0 Agrees | 0 Disagrees | Report Abuse »
"Baloney on Obamacare"
0 Agrees | 0 Disagrees | Report Abuse »
Hello Capricorn, it may bother me indeed. It does not surprise me but yep, it is likely quite unfair.. never fear, perhaps the 41st time house republicans try to veto this law will be the one that works. More likely, it will be yet another exercise in futility by our fiscally conservative republican legislators.. yep, that's an oxymoron. Off to Wegmans..
1 Agrees | 2 Disagrees | Report Abuse »
Buff, does it not trouble you that our representatives have exempted themselves from this so called excellent legislation? I find that fact alone not only unfair, but completely unethical.
4 Agrees | 2 Disagrees | Report Abuse »
Excellent letter, folks.. to parse the tax comment, could not the same argument be made for any tax on business? As anything, taxes, increases in rent, the costs are ultimately passed on to consumers..
4 Agrees | 2 Disagrees | Report Abuse »
Chuck it has nothing to do with hating Obama. It has everything to do with opposing legislation that the majority of Americans are opposed to and that was forced upon us. Time will allow you to see this more clearly if you allow yourself to see the facts for what they are without being blinded by party loyalty.
7 Agrees | 4 Disagrees | Report Abuse »
Good letter! But the braindead, Obama hating right will call it a lie.
4 Agrees | 7 Disagrees | Report Abuse »
Yes, another liberal idiot who thinks taxing manufacturers means consumers will not pay more.
Just as the original letter lost credibility for delineating the taxable items incorrectly, this letter has lost credibility due to its clear lack of economic understanding.
9 Agrees | 5 Disagrees | Report Abuse »
Ritty, I agree. I think her letter lost all credibility after that one statement.
8 Agrees | 4 Disagrees | Report Abuse »
"These taxes will all be paid by manufacturers and importers, not consumers."
8 Agrees | 3 Disagrees | Report Abuse »
Showing 10 of 10 comments
Post a Comment
You must first login before you can comment.


text:
fosun international ltd
(656:Stock Exchange of Hong Kong Limited)
Executive Profile*
John William Snow Ph.D.
Consultant of the Board,Fosun International Limited
|Total Calculated Compensation
|This person is connected to 78 board members in 7 different organizations across 25 different industries.
See Board Relationships
Dr. John William Snow, Ph.D. has been the President of JWS Associates, LLC since October 2006. Dr. Snow has been a Consultant of the Board at Fosun International Ltd since 2010. He served as the President, Chairman and Chief Executive Officer at CSX Corporation from April 1989 till 2003. He served at Federated Equity Funds - Federated Prudent Bear Fund. Dr. Snow served as U.S. Secretary of United States Department of The Treasury from February 2003 to June 2006. His ...
Corporate Headquarters*
No. 2 East Fuxing RoadPhone: 86 21 6332 5858
Shanghai, -- 200010
Fax: 86 21 6332 5028
Board Members Memberships*
Director, Member of Compensation Committee and Member of Corporate Governance & Nominating Committee
Lead Independent Director and Chairman of Compensation Committee
Director of Dominion Midstream GP LLC, Member of Audit Committee and Member of Conflicts Committee
Master's Degree
Johns Hopkins University
University of Virginia
The George Washington University
Bachelor's Degree 1962
The University of Toledo
Unknown/Other Education
Kenyon College
Other Affiliations*
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
|There is no Competitor Compensation data available.
Sponsored Financial Commentaries
Sponsored Links
Only a company representative may request an update for the company profile. Documentation will be required.
To contact FOSUN INTERNATIONAL LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at firstname.lastname@example.com.